Japan patent granted
Unique oral peptide delivery technology
Superior oral bioavailability compared to state-of-the-art peptide tablet technologies
Strong expertise and experience in oral delivery of GLP-1 peptides
Oral delivery of PROTACs and other Biopharmaceutics Classification System injectable (BCS Class IV) drugs
CYPRUMED | Oral Peptide Delivery Experts
Drug delivery technologies for the non-invasive administration of biologics. We are collaborating with various pharma partners, including Bayer, Boehringer Ingelheim and Ferring.
Areas of expertise
Cyprumed specializes in innovative oral delivery solutions for peptides such as GLP-1 agonists and Biopharmaceutics Classification System injectable (BCS Class IV) drugs, offering superior tablet formulations for enhanced bioavailability. With its team of experts and network, and its proprietary delivery platform, Cyprumed is at the forefront of the oral drug delivery technology industry. Cyprumed enables the transformation of novel peptides and BCS IV compounds into high-quality oral drug products.
Cyprumed technology
The Cyprumed technology offers advantages over current delivery systems. We offer three oral drug delivery platforms: intestinal and gastric peptide delivery, and oral delivery of Biopharmaceutics Classification System injectable (BCS Class IV) drugs. By selecting the right delivery platform for your compound, we can make your API orally bioavailable.
„Our technology is not only highly efficient, but also easy to produce and scale-up, while fulfilling key regulatory requirements.“
Florian Föger, PhD, CEO
Florian Föger, PhD, CEO
Latest news
January, 2024
September – December, 2023
Cyprumed enters into additional pharma collaborations
February, 2023
Cyprumed expands its lab capabilities to strengthen bioanalytics
Want to collaborate?
Are you interested in a possible collaboration? Do you have any questions? We look forward to hearing from you!